Analysis

Genelux Corporation (GNLX) Stock Analysis

Genelux Corporation investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to GNLX.

websiteGNLX/analysis/GNLX

Genelux Corporation

Genelux Corporation investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to GNLX.

Stock profile

Ticker

GNLX

Asset type

Stock

Market cap

$133.0M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Genelux Corporation may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • GNLX primary listing

Latest Genelux Corporation news

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with addi...

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated...

Genelux Corporation to Participate in Upcoming Conferences

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company w...

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindri...

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pr...

Research sections

Valuation

Review valuation context for Genelux Corporation.

Future growth

Review future growth context for Genelux Corporation.

Past performance

Review past performance context for Genelux Corporation.

Financial health

Review financial health context for Genelux Corporation.

Dividend

Review dividend context for Genelux Corporation.

Management

Review management context for Genelux Corporation.

Ownership

Review ownership context for Genelux Corporation.

Other information

Review other information context for Genelux Corporation.

Community

Review community context for Genelux Corporation.